Bamco Inc. NY Sells 347,213 Shares of Schrödinger, Inc. (NASDAQ:SDGR)

Bamco Inc. NY cut its stake in shares of Schrödinger, Inc. (NASDAQ:SDGR) by 90.8% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 35,000 shares of the company’s stock after selling 347,213 shares during the quarter. Bamco Inc. NY’s holdings in Schrödinger were worth $945,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. International Assets Investment Management LLC lifted its holdings in shares of Schrödinger by 3,480.0% during the fourth quarter. International Assets Investment Management LLC now owns 1,790 shares of the company’s stock valued at $64,000 after acquiring an additional 1,740 shares during the period. GAMMA Investing LLC acquired a new stake in Schrödinger in the fourth quarter worth about $67,000. PNC Financial Services Group Inc. grew its position in shares of Schrödinger by 186.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,127 shares of the company’s stock worth $76,000 after buying an additional 1,385 shares during the period. Quest Partners LLC acquired a new position in shares of Schrödinger during the 4th quarter worth about $153,000. Finally, SG Americas Securities LLC grew its position in shares of Schrödinger by 8.4% during the 4th quarter. SG Americas Securities LLC now owns 5,125 shares of the company’s stock worth $183,000 after buying an additional 397 shares during the period. 79.05% of the stock is owned by institutional investors.

Schrödinger Trading Down 0.9 %

SDGR stock traded down $0.20 during trading hours on Monday, hitting $22.22. 246,423 shares of the stock were exchanged, compared to its average volume of 791,324. The firm has a market capitalization of $1.61 billion, a P/E ratio of -11.93 and a beta of 1.51. The company has a 50-day simple moving average of $21.21 and a two-hundred day simple moving average of $24.62. Schrödinger, Inc. has a 12 month low of $18.21 and a 12 month high of $52.81.

Schrödinger (NASDAQ:SDGR) last posted its quarterly earnings data on Wednesday, May 1st. The company reported ($0.76) earnings per share for the quarter, hitting the consensus estimate of ($0.76). Schrödinger had a negative return on equity of 29.25% and a negative net margin of 75.94%. The firm had revenue of $36.60 million for the quarter, compared to analysts’ expectations of $41.23 million. On average, equities research analysts predict that Schrödinger, Inc. will post -2.83 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. KeyCorp decreased their target price on Schrödinger from $30.00 to $25.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Leerink Partnrs upgraded Schrödinger to a “strong-buy” rating in a research note on Tuesday, July 2nd. Craig Hallum cut their price objective on Schrödinger from $35.00 to $30.00 and set a “buy” rating for the company in a report on Thursday, May 2nd. Citigroup cut their price objective on Schrödinger from $39.00 to $37.00 and set a “buy” rating for the company in a report on Thursday, May 2nd. Finally, SVB Leerink initiated coverage on Schrödinger in a report on Tuesday, July 2nd. They set an “outperform” rating and a $29.00 price target for the company. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Schrödinger currently has an average rating of “Moderate Buy” and an average target price of $38.90.

Schrödinger Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.